PROVECTUS BIOPHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

PROVECTUS BIOPHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $336.1 thousand for the year ending 2025.

  • PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -45.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 66.0%.
  • Historical annual values: Fiscal year 2025: $336.1 thousand | Fiscal year 2024: $617.1 thousand | Fiscal year 2023: $557.7 thousand | Fiscal year 2022: $989.0 thousand.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: